<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101151</url>
  </required_header>
  <id_info>
    <org_study_id>VDIS</org_study_id>
    <nct_id>NCT02101151</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)</brief_title>
  <acronym>VDIS</acronym>
  <official_title>Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rashid Centre for Diabetes and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rashid Centre for Diabetes and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of type 2 diabetes mellitus and obesity is increasing at an alarming rate both&#xD;
      nationally and worldwide. Accumulating evidence suggests that serum cholecalciferol levels&#xD;
      may be inversely related to the prevalence of diabetes, insulin resistance and metabolic&#xD;
      syndrome. However, to demonstrate a causal relation between vitamin D and glucose metabolism,&#xD;
      evidence from randomized and adequately powered placebo-controlled intervention trials is&#xD;
      needed.The trials available on the effect of Vitamin D supplementation are not conclusive.&#xD;
      Hence, the purpose of this study was to conduct a double-blind randomized trial in Vitamin D&#xD;
      deficient obese type 2 diabetic Emirati population to clarify the effect of vitamin D&#xD;
      supplementation on glycemic control and obesity parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D insufficiency has been reported as a risk factor for the development of type 1 and&#xD;
      type 2 diabetes mellitus. In contrast to the findings of the observational studies, the&#xD;
      supplementation trials in type 2 diabetes mellitus (T2DM) do not report any definitive&#xD;
      conclusions, but it does suggest that supplementation at an early stage in the development of&#xD;
      diabetes may be of benefit in delaying progression to clinical T2DM by increasing the&#xD;
      pancreatic insulin release and improved insulin resistance plus impaired glucose&#xD;
      tolerance.There is also speculation on role of vitamin D in physiology of weight loss and&#xD;
      body composition.However, there have been multiple inconsistencies within the reported trial&#xD;
      i.e. sample size, dose of vitamin D, frequency of supplementation, and population studied.&#xD;
&#xD;
      Hence the randomised clinical trial was undertaken to study the effect of vitamin D&#xD;
      (Cholecalciferol) supplementation on metabolic markers and obesity parameters in the vitamin&#xD;
      D deficient obese type 2 diabetic subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycemic control</measure>
    <time_frame>6 months</time_frame>
    <description>HbA1c, Fasting Blood glucose, C-peptide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile</measure>
    <time_frame>6 months</time_frame>
    <description>Serum Total cholesterol, LDL-C, HDL-C, Triglyceride, Apolipoprotein A and B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D</measure>
    <time_frame>6 months</time_frame>
    <description>Serum 25-hydroxyvitamin D, Parathyroid hormone, Calcium, Phosphate, Alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other metabolic markers</measure>
    <time_frame>6 months</time_frame>
    <description>High sensitive C-Reactive Protein, Creatinine, Thyroid stimulating hormone, Systolic Blood pressure, Diastolic Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity Parameter</measure>
    <time_frame>6 monhts</time_frame>
    <description>Weight, BMI, waist circumference, Fat mass, Muscle mass, water mass</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (starch) capsules identical to vitamin D capsules in appearance</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3(cholecalciferol)</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Vitamin D3 group</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  United Arab Emirates national&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Age 30-65 years&#xD;
&#xD;
          -  Diagnosed as type 2 diabetes&#xD;
&#xD;
          -  Body Mass Index ≥30 kg/m2&#xD;
&#xD;
          -  Serum 25 hydroxy Vitamin D ≤ 50nmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  History or evidence of liver failure (elevated liver function tests) or renal failure&#xD;
             ( elevated creatinine)&#xD;
&#xD;
          -  History of malabsorption syndrome.&#xD;
&#xD;
          -  On vitamin D Supplementation&#xD;
&#xD;
          -  On hormone replacement therapy&#xD;
&#xD;
          -  On corticosteroids, anticonvulsants, AIDS medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rashid Centre for Diabetes and Research</name>
      <address>
        <city>Ajman</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2014</study_first_posted>
  <last_update_submitted>March 29, 2014</last_update_submitted>
  <last_update_submitted_qc>March 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rashid Centre for Diabetes and Research</investigator_affiliation>
    <investigator_full_name>Dr.Amena Sadiya</investigator_full_name>
    <investigator_title>Senior Nutritionist</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>vitamin D</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

